A Look At CSL (ASX:CSL) Valuation After Seqirus Demerger Plan CEO Exit And Ongoing Share Price Weakness

Rising interest in CSL (ASX:CSL) has been sparked by a mix of setbacks and corporate moves, including a planned demerger of its CSL Seqirus flu vaccine business, the CEO’s resignation, operational pressures, and ongoing buybacks and dividends.

See our latest analysis for CSL.

At a recent share price of A$119.88, CSL’s short term share price return has been weak, with a 1 month share price decline of 15.68% and a 90 day share price decline of 33.58%. The 1 year total shareholder return of 48.67% and 5 year total shareholder return of 53.44% underline how sentiment has faded as the Seqirus demerger, CEO change and operational issues have come into focus alongside ongoing buybacks and dividends.

If you are reassessing your healthcare exposure after CSL’s recent moves, it could be worth widening the net to other biotech and pharma opportunities using our 9 healthcare AI stocks

With CSL’s share price under pressure despite ongoing revenue and profit growth and a sizeable gap to analyst price targets, the key question is whether recent setbacks are already reflected in the price or if the stock still assumes stronger future growth.

Most Popular Narrative: 54.5% Undervalued

According to Ramsee, the most followed narrative on CSL values the stock at A$263.33 per share, well above the recent A$119.88 close, using a 4.0% discount rate.

The baseline valuation reflects CSL''s strong underlying business fundamentals, driven by robust growth in its core Immunoglobulin (Ig) franchise, ongoing gross margin recovery in the CSL Behring segment, and contributions from Seqirus and Vifor, albeit with some near-term headwinds for the latter two.

CSL Limited exhibits strong fundamental characteristics, underpinned by leadership in plasma therapies and influenza vaccines, a robust R&D pipeline, and clear drivers for earnings growth, particularly the ongoing recovery of CSL Behring''s gross margin. Read the complete narrative.

Curious what kind of earnings trajectory, margin rebuild and long term cash flow profile sit behind that valuation gap? The full narrative spells out those assumptions in detail.

Result: Fair Value of A$263.33 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, recent US tariff policy shifts and execution risk around plasma margin recovery could still undermine this thesis and keep the stock under pressure.

Find out about the key risks to this CSL narrative.

Another View: What Earnings Multiples Are Signalling

While the narrative and SWS DCF work suggest CSL is undervalued, the current P/E of 30.2x tells a different story. It sits above both the Global Biotechs average of 27.7x and the stock's own fair ratio of 40.4x that the market could move towards over time.

That mix of a discount to SWS DCF value and a premium to peer multiples creates a tug of war between long term cash flow potential and what investors are willing to pay for near term earnings today. The question is which signal to put more weight on as the CSL story evolves.

See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With sentiment clearly split between risks and rewards, now is a good time to look through the data yourself and decide where you stand using our 3 key rewards and 4 important warning signs

Looking for more investment ideas?

If CSL has sharpened your thinking, do not stop here. Use targeted stock ideas to round out your watchlist and keep fresh opportunities on your radar.

• Focus on potential mispriced opportunities by tapping into 10 high quality undervalued stocks before others spot them.
• Strengthen your income stream by scanning 6 dividend fortresses that could complement growth focused holdings.
• Prioritise resilience by reviewing 6 resilient stocks with low risk scores that aim to keep volatility in check while you stay invested.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com